Pfizer Corporation

Lewin Theophilus Wint

George Joseph Quallich

Terry J Rosen

Dennis Michael Godek

Peter Robert Rose

Charles K Chiu

Sally Gut

George Chang

Michael J Castaldi

Stephen S Massett

Glenn R Williams

Phillip James Johnson

The present invention is directed to certain pharmaceutically acceptable salts of the therapeutically potent selective serotonin reuptake inhibitor, sertraline: and pharmaceutical compositions thereof, wherein said salts are selected from the group consisting of the p-toluenesulfonic acid salt, the fumaric acid salt, the benzenesulfonic acid salt, the benzoic acid salt, the L-tartaric acid salt and the (&#x2212;)-camphor-10-sulfonic acid salt.

Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof

A process for preparing a naphthyridone carboxylic acid and its derivatives makes use of side chain intermediates of formulae I and IV herein.

Process for preparing naphthyridones and intermediates

Citric acid salt of a therapeutic compound and pharmaceutical compositions thereof

Succinic acid salts of 5,7,14-triazatetracyclo&lsqb;10.3.1.02,11.04,9&rsqb; -hexadeca-1(11),3,5,7,9-pentaene and pharmaceutical compositions thereof

Citrate salt of 5,8,14-triazatetracyclo&lsqb;10.3.1.02,11.04,9&rsqb;-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof

Two crystalline polymorphic forms of (2-Benzhydryl-1-azo-bicyclo&lsqb;2.2.2&rsqb;oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate monohydrate (the monohydrates) are Form A and Form B. The pharmaceutical composition containing at least one of these polymorphs has advantageous stability for formulation to treat acute emesis in patient receiving chemotherapy. The administration of this pharmaceutical composition is conventional oral by preferably tablet or capsule and intravenous. A method of making A and B Forms is also disclosed.

Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions

A single crystalline polymorphic form (2S,3S)-N-(methoxy-5-t-butylphenylmethyl-2-diphenylmethyl-1-azobicyclo&lsqb;2,2,2&rsqb; octan-3-amine citrate(citrate monohydrate) and its pharmaceutical composition. The pharmaceutical composition of the polymorphic form if the citrate monohydrate has advantageous stability for formulation to treat emesis. The administration of this pharmaceutical composition is immediate release, oral dosage form preferably by tablet or capsule or intravenous.

Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions

A hydrochloride salt of an Apo B secretion/MTP inhibitor, methods of making the salt, methods of using the salt and pharmaceutical compositions containing the salt are disclosed.

Apo B-secretion/MTP inhibitor hydrochloride salt

Novel processes are disclosed for the preparation and resolution of substituted piperidines of the formula ##STR1## wherein R.sup.1 and R.sup.2 are defined as below, and related compounds, as well as novel intermediates used in such processes.

Preparation of substituted piperidenes

Substituted piperidines and related compounds of the formula ##STR1## wherein R.sup.1 and R.sup.2 are herein defined are disclosed.

Growing community of inventors

Wilmette, IL, United States of America

Lewin Theophilus Wint